Shuo Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shuo Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Hao Chen
The First Affiliated Hospital of Nanchang University, Nanchang, China
1 shared publication - Haoyu Wang
Children’s Hospital of Nanjing Medical University
1 shared publication Hua-Sheng Shi
Liver Disease Center, Affiliated Hospital of Qingdao University, Qingdao, China
1 shared publication- Jieying Tang
Department of Plastic Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University , No. 168 Litang Road, Changping District, Beijing 102218
1 shared publication - Junli Zhao
College of Computer Science and Technology, Qingdao University, Qingdao, China
1 shared publication - Liqun Wu
Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China
1 shared publication
Latest Publications
- Open Access
- 23 September 2022
- Published by Association for Computing Machinery (ACM)
- p. 302-307
3D Skull Similarity Evaluation Based on Siamese Network with Residual Structure
The similarity evaluation of skull data is a research work of great significance and has been widely used in forensic, archaeology, and other fields. In this paper, we propose a 3D skull similarity evaluation method based on Siamese Network. Firstly, the original 3D skull data are mapped onto 2D depth images, which maintains the original information of the 3D data to the greatest extent. Then, we introduce the residual structure into the Siamese network to extract the main features of any pair of skull depth image data and map it to a new space for representation. Finally, a mapping function is proposed to calculate a reasonable similarity value of 0-1 between the two input skull data through the sigmoid layer. We conducted objective experiments on 3D skull models and compared them with the subjective skull similarity. The experimental results show that the 3D skull similarity evaluation method based on Siamese network with residual structure can effectively evaluate the similarity of skulls. The results are basically consistent with people's subjective evaluation, providing an effective direction for craniofacial reconstruction and identification.
- 23 September 2022
- Published by Association for Computing Machinery (ACM)
- p. 302-307
Open Access3D Skull Similarity Evaluation Based on Siamese Network with Residual Structure
The similarity evaluation of skull data is a research work of great significance and has been widely used in forensic, archaeology, and other fields. In this paper, we propose a 3D skull similarity evaluation method based on Siamese Network. Firstly, the original 3D skull data are mapped onto 2D depth images, which maintains the original information of the 3D data to the greatest extent. Then, we introduce the residual structure into the Siamese network to extract the main features of any pair of skull depth image data and map it to a new space for representation. Finally, a mapping function is proposed to calculate a reasonable similarity value of 0-1 between the two input skull data through the sigmoid layer. We conducted objective experiments on 3D skull models and compared them with the subjective skull similarity. The experimental results show that the 3D skull similarity evaluation method based on Siamese network with residual structure can effectively evaluate the similarity of skulls. The results are basically consistent with people's subjective evaluation, providing an effective direction for craniofacial reconstruction and identification.
- 12 March 2021
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 12 (11) , 4960-4971
Enzymatically synthesized α-galactooligosaccharides attenuate metabolic syndrome in high-fat diet induced mice in association with the modulation of gut microbiota
The composition and structure of gut microbiota plays an important role in obesity induced by a high-fat diet (HFD) and related metabolic syndrome (MetS).
- 12 March 2021
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 12 (11) , 4960-4971
Enzymatically synthesized α-galactooligosaccharides attenuate metabolic syndrome in high-fat diet induced mice in association with the modulation of gut microbiota
The composition and structure of gut microbiota plays an important role in obesity induced by a high-fat diet (HFD) and related metabolic syndrome (MetS).
- Open Access
- 27 May 2020
- Published by S. Karger AG in Visceral Medicine
- Vol. 37 (2) , 116-119
A Hepatocellular Carcinoma Patient with TSC1 Mutations Benefits from Treatment with Everolimus: A Case Report
Hepatocellular carcinoma (HCC) has a high degree of malignancy and poor prognosis. Treatment options for patients with advanced HCC are limited. There is currently no evidence to approve the accumulation of targeted therapies for HCC to support the inhibition of the PI3K/Akt/mTOR signaling pathway as an effective therapeutic strategy. We report on a patient with advanced HCC carrying the TSC1 gene mutation who responded well to the mammalian target of rapamycin inhibitor everolimus. Computed tomography revealed tumor shrinkage and maintenance of partial remission after everolimus treatment for >12.3 months. To the best of our knowledge, this is the first clinical case report showing benefit from everolimus treatment in HCC patients with TSC1 gene mutations. Therefore, everolimus may be used as a potential targeted therapy for HCC with TSC1 gene mutation.
- 27 May 2020
- Published by S. Karger AG in Visceral Medicine
- Vol. 37 (2) , 116-119
Open AccessA Hepatocellular Carcinoma Patient with TSC1 Mutations Benefits from Treatment with Everolimus: A Case Report
Hepatocellular carcinoma (HCC) has a high degree of malignancy and poor prognosis. Treatment options for patients with advanced HCC are limited. There is currently no evidence to approve the accumulation of targeted therapies for HCC to support the inhibition of the PI3K/Akt/mTOR signaling pathway as an effective therapeutic strategy. We report on a patient with advanced HCC carrying the TSC1 gene mutation who responded well to the mammalian target of rapamycin inhibitor everolimus. Computed tomography revealed tumor shrinkage and maintenance of partial remission after everolimus treatment for >12.3 months. To the best of our knowledge, this is the first clinical case report showing benefit from everolimus treatment in HCC patients with TSC1 gene mutations. Therefore, everolimus may be used as a potential targeted therapy for HCC with TSC1 gene mutation.